Philips to buy cardiac devices firm Spectranetics for US$1.7b
London
ROYAL Philips NV's US$1.7 billion deal to buy Spectranetics Corp, a US maker of devices to treat cardiac disease, shows the Dutch company is moving more aggressively to bolster its growing health-care business.
Philips will offer US$38.50 a share in cash for the Colorado Springs-based company, according to a statement on Wednesday. The price is 27 per cent above Spectranetics' closing level on Tuesday. Philips also will buy back as much as 1.5 billion euros (S$2.4 billion) of its own stock to offset share dilution from an employee incentive programme.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
Wall Street Journal moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue